LncRNA NKILA correlates with the malignant status and serves as a tumor‐suppressive role in rectal cancer

Abstract

NF-κB interacting lncRNA (NKILA) has been found to function as a tumor-suppressive role in various human cancers. However, the role of NKILA in rectal cancer is still unknown. The objective of this study is to investigate the clinical value and biological function of NKILA in rectal cancer. The association between NKILA expression and clinical variables including prognosis was estimated in rectal cancer patients. The gain-of-function study of NKILA in rectal cancer cell was conducted to evaluate the effect of NKILA on cell proliferation, migration, invasion, and NF-κB signaling pathway. The results suggested NKILA expression was decreased in rectal cancer tissues and cells, and correlated with clinical stage, T classification, N classification and M classification. NKILA low-expression was an independent poor prognostic factor in rectal cancer patients. NKILA-inhibited rectal cancer cell proliferation, migration, and invasion via suppressing NF-κB signaling. In conclusion, NKILA serves as an antioncogenic lncRNA in rectal cancer.

Expression Level and Clinical Significance of NKILA in Human Cancers: A Systematic Review and Meta-Analysis

“…The present study emphasises on the lncRNA, which is known as NKILA , a NF- κ B-induced lncRNA; in comparison to others, it is a novel form of lncRNA that maps to chromosome 20q13 [ 14 , 15 ]. Studies have documented that it has useful functionality in suppressing the growth of cancer genes in a variety of cancers, such as esophageal squamous cell carcinoma [ 16 ], laryngeal cancer [ 17 ], nasopharyngeal carcinoma [ 18 ], rectal cancer [ 19 ], tongue squamous cell carcinoma [ 20 ], and colorectal cancer [ 21 ].…”

Epigenetic Silencing of Tumor Suppressor lncRNA NKILA: Implication on NF-κB Signaling in Non-Hodgkin’s Lymphoma

“…Furthermore, as a transcription factor, NF-κB regulates expression of multiple downstream effectors, enhancing cell proliferation, inhibiting cell apoptosis, or promoting cell migration and invasion [32]. Herein, in NHL cells, down-regulation of NKILA resulted in increase of cellular proliferation and decrease of cell death, consistent with the tumor suppressor role of NKILA in multiple tumors, including melanoma, lung cancer, rectal cancer, laryngeal cancer and breast cancer [19,20,[33][34][35][36]. In addition, NKILA has also been shown to inhibit tumor invasion and migration in epithelial cancers, such as breast cancer, hepatocellular carcinoma and tongue squamous cell carcinoma [19,36,37].…”

LncRNA NKILA was upregulated in diabetic cardiomyopathy with early prediction values

“…Expression of lncRNA NKILA has been extensively investigated in many types of cancer in humans (13,14,16,17). As a tumor suppressor lncRNA, NKILA expression has been illustrated to be downregulated in various types of cancer malignancies, while its upregulation inhibits cancer development (16). The 8-year-follow-up study presented here revealed that lncRNA NKILA expression was specifically upregulated with the occurrence of DC.…”